I assume Gold is referring to this statement in the last announcement:
The Company notes that one of those therapies, enzalutamide, was the subject of a US$14 billion
acquisition by Pfizer in 2016, approved for marketing in 2012 on the basis of a 5-month increase in mOS
from 13.6 to 18.4 months. Again, it is worth noting that the LuPIN outcome of 19.7 months has been
achieved in men whose cancer has already progressed on enzalutamide.
It's a little bit incorrect to conflate the valuation of enzalutamide and the basis of it's marketing approval. But, it is something to consider.
- Forums
- ASX - By Stock
- NOX
- LuPIN abstract
LuPIN abstract, page-23
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M |
Open | High | Low | Value | Volume |
11.0¢ | 11.0¢ | 10.0¢ | $11.03K | 105.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 418372 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 102513 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 408372 | 0.100 |
1 | 10312 | 0.097 |
2 | 52630 | 0.095 |
1 | 35000 | 0.094 |
1 | 53000 | 0.093 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 102513 | 3 |
0.115 | 64000 | 1 |
0.120 | 38999 | 2 |
0.125 | 68500 | 4 |
0.130 | 418489 | 6 |
Last trade - 15.45pm 27/09/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |